A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer

Sponsor

Celgene (Industry)

Overall Status

Active, not recruiting

CT.gov ID

NCT03850067

Collaborator

(none)

Enrollment

Locations

Arms

63.3

Anticipated Duration (Months)

3.5

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

CC-90011-SCLC-001 is a multicenter, Phase 1b, open-label, dose finding study to assess the safety, tolerability, and preliminary efficacy of CC-90011 given concurrently and sequentially to standard of care platinum-based, cisplatin and etoposide, carboplatin and etoposide and/or etoposide and Nivolumab to subjects with first line ES SCLC.

The dose finding part of the study will explore escalating oral doses of CC-90011 in combination with cisplatin, etoposide and/or carboplatin with or without Nivolumab (chemotherapy), to determine the maximum tolerated dose of CC- 90011 in combination with chemotherapy with or without Nivolumab to subjects with first line ES SCLC.

Condition or Disease	Intervention/Treatment	Phase
Small Cell Lung Carcinoma	Drug: CC-90011 Drug: Cisplatin Drug: Carboplatin Drug: Etoposide Drug: Nivolumab	Phase 1

Study Design

Study Type:

Interventional

Anticipated Enrollment :

90 participants

Allocation:

Non-Randomized

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase 1b, Multicenter, Open-label, Dose Finding Study to Assess the Safety, Tolerability, and Preliminary Efficacy of CC-90011 Given in Combination With Cisplatin and Etoposide in First Line, Extensive Stage Subjects With Small Cell Lung Cancer

Actual Study Start Date :

Mar 12, 2019

Anticipated Primary Completion Date :

Sep 5, 2023

Anticipated Study Completion Date :

Jun 21, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: CC-90011 in combination with Cisplatin and Etoposide During the Chemotherapy Treatment Period, the dose escalation is designed to explore three dose levels of CC-90011, for example 20, 40, and 60 mg as determined by Bayesian design, administered orally Days 1 and 8, in combination with cisplatin intravenous (IV) 75 mg/m2, Day 1, and etoposide iv 100 mg/m2 on Days 1, 2, and 3, for 4 cycles of 21 days each. Subjects completing the chemotherapy and being responders as per RECIST 1.1 will enter the Maintenance Treatment Period. Subjects completing 6 cycles of maintenance treatment subject will be treated only with CC-90011 at RP2D (60 mg) and continuing on CC-90011 are only required to have clinic visits/assessments performed on Day 1 (± 3 days) of each subsequent cycle (Cycles 6 and higher) unless more frequent visits are clinically indicated.	Drug: CC-90011 CC-90011 Drug: Cisplatin Cisplatin
Experimental: CC-90011 in combination with Carboplatin and Etoposide During the Chemotherapy Treatment Period, the dose escalation is designed to explore three dose levels of CC-90011, for example 20, 40, and 60 mg as determined by Bayesian design, administered orally Days 1 and 8, in combination with cisplatin intravenous (IV) 75 mg/m2, Day 1, and etoposide iv 100 mg/m2 on Days 1, 2, and 3, for 4 cycles of 21 days each. Subjects completing the chemotherapy and being responders as per RECIST 1.1 will enter the Maintenance Treatment Period. Subjects completing 6 cycles of maintenance treatment subject will be treated only with CC-90011 at RP2D (60 mg) and continuing on CC-90011 are only required to have clinic visits/assessments performed on Day 1 (± 3 days) of each subsequent cycle (Cycles 6 and higher) unless more frequent visits are clinically indicated	Drug: Carboplatin Carboplatin Drug: Etoposide Etoposide
Experimental: Nivolumab combination When the RP2D of CC-90011 in combination with cisplatin or carboplatin and etoposide is determined, the combination of CC-90011 at RP2D with cisplatin or carboplatin and etoposide plus nivolumab IV 240 mg Day 1 of each chemotherapy cycle, will be explored. For CC-90011 in combination with chemotherapy and nivolumab, the starting dose will be the RP2D of CC-90011 in combination with chemotherapy. A maintenance therapy will be given to subjects responding to the combination of CC-90011 with chemotherapy or to chemotherapy with nivolumab, as per RECIST 1.1. These subjects will receive 60 mg or 40 mg (in case of combination with nivolumab) of CC-90011 orally once weekly on Days 1, 8, 15, and 22, during cycles of 28-day each and, in the case of the combination with nivolumab, nivolumab IV 480 mg on Day 1 during cycles of 28-day each.	Drug: Nivolumab Nivolumab

Arm

Intervention/Treatment

Experimental: CC-90011 in combination with Cisplatin and Etoposide

During the Chemotherapy Treatment Period, the dose escalation is designed to explore three dose levels of CC-90011, for example 20, 40, and 60 mg as determined by Bayesian design, administered orally Days 1 and 8, in combination with cisplatin intravenous (IV) 75 mg/m2, Day 1, and etoposide iv 100 mg/m2 on Days 1, 2, and 3, for 4 cycles of 21 days each. Subjects completing the chemotherapy and being responders as per RECIST 1.1 will enter the Maintenance Treatment Period. Subjects completing 6 cycles of maintenance treatment subject will be treated only with CC-90011 at RP2D (60 mg) and continuing on CC-90011 are only required to have clinic visits/assessments performed on Day 1 (± 3 days) of each subsequent cycle (Cycles 6 and higher) unless more frequent visits are clinically indicated.

Drug: CC-90011

CC-90011

Drug: Cisplatin

Cisplatin

Experimental: CC-90011 in combination with Carboplatin and Etoposide

Drug: Carboplatin

Carboplatin

Drug: Etoposide

Etoposide

Experimental: Nivolumab combination

When the RP2D of CC-90011 in combination with cisplatin or carboplatin and etoposide is determined, the combination of CC-90011 at RP2D with cisplatin or carboplatin and etoposide plus nivolumab IV 240 mg Day 1 of each chemotherapy cycle, will be explored. For CC-90011 in combination with chemotherapy and nivolumab, the starting dose will be the RP2D of CC-90011 in combination with chemotherapy. A maintenance therapy will be given to subjects responding to the combination of CC-90011 with chemotherapy or to chemotherapy with nivolumab, as per RECIST 1.1. These subjects will receive 60 mg or 40 mg (in case of combination with nivolumab) of CC-90011 orally once weekly on Days 1, 8, 15, and 22, during cycles of 28-day each and, in the case of the combination with nivolumab, nivolumab IV 480 mg on Day 1 during cycles of 28-day each.

Drug: Nivolumab

Nivolumab

Outcome Measures

Primary Outcome Measures

Dose-Limiting Toxicity (DLT) [Up to approximately 2 years]
A DLT is defined as any of the toxicities described in the protocol occurring within the DLT assessment unless the event can clearly be determined to be unrelated to CC-90011
Maximum Tolerated Dose (MTD) [Up to approximately 2 years]
MTD is the highest dose that causes DLTs in not more than 33% of the subjects treated with CC-90010 in the first cycle with at least 6 evaluable subjects treated at this dose
Adverse Events (AEs) [Up to approximately 3 years]
An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE

Secondary Outcome Measures

Objective Response Rate (ORR) [Up to approximately 2 years]
Is defined as the percent of subjects whose best response is complete response (CR) or partial response (PR).
Progression-free Survival (PFS) [Up to approximately 2 years]
Is defined as the time from the first dose of study drug to the first occurrence of disease progression or death from any cause.
Overall Survival (OS) [Up to approximately 2 years]
Is measured as the time from the first dose of CC-90011 to death due to any cause.
Pharmacokinetics- Cmax [Up to approximately 2 years]
Maximum observed plasma concentration
Pharmacokinetics- AUC [Up to approximately 2 years]
Area under the plasma concentration time-curve
Pharmacokinetics- Tmax [Up to approximately 2 years]
Time to maximum plasma concentration
Pharmacokinetics- t1/2 [Up to approximately 2 years]
Terminal half-life
Pharmacokinetics- CL/F [Up to approximately 2 years]
Apparent clearance
Pharmacokinetics- VzF [Up to approximately 2 years]
Apparent volume of distribution

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Male and female subject is 18 years of age or older at the time of signing the informed consent form (ICF).
Subject with histological or cytological confirmation of extensive stage SCLC according to 2015 WHO classification (Travis, 2015).
Subject must be able to provide fresh or archival tumor tissues
Subject is found suitable for at least 4 cycles of platinum-based standard chemotherapy.
Subject has at least 1 site of measurable disease per RECIST 1.1.
Subject must have the following laboratory values:

• Absolute neutrophil count (ANC) ≥ 1.5 x 109/L

• Hemoglobin (Hgb) ≥ 10 g/dL (≥ 100 g/L or > 6.2 mmol/L)

Platelet count (Plt) ≥ 150 x 109/L
Serum aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine aminotransferase/serum glutamate pyruvate transaminase (ALT/SGPT) ≤ 3.0 x upper limit of normal (ULN) or ≤ 5.0 x ULN if liver metastases are present
Serum total bilirubin ≤ 1.5 x ULN
Serum creatinine ≤ 1.5 mg/dL or creatinine clearance ≥ 60 mL/min (see Appendix G to see creatinine clearance formula). For the purposes of this protocol, the glomerular filtration rate (GFR) is considered to be equivalent to the creatinine clearance.
Prothrombin time (or international normalized ratio [INR]) and activated partial thromboplastin time (APTT) ≤ 1.5 ULN

Females of childbearing potential (FCBP) must:

• Either commit to true abstinence from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use one highly effective contraceptive method plus one barrier method.

Have two negative pregnancy tests as verified by the Investigator prior to starting CC-90011:
a negative serum pregnancy test (sensitivity of at least 25 mIU/mL) at Screening
a negative serum or urine pregnancy test within 24 hours prior to Cycle 1 Day 1 of study treatment.
a negative Serum or urine within 24 hours prior to first dose of nivolumab and then every 4 weeks (± 1 week) regardless of dosing schedule.
Avoid conceiving for 6 months after last dose of cisplatin or carboplatin or etoposide, or 5 months after last dose of nivolumab for FCBP, or 45 days after the last dose of CC-90011, whichever is the latest.
Agree to ongoing pregnancy testing during the course of the study, and after the end of study treatment. This applies even if the subject practices true abstinence from heterosexual contact.

Males must practice true abstinence from heterosexual intercourse (which must be reviewed on a monthly basis) or agree to use a condom (a latex condom is recommended) during sexual contact with a pregnant female or an FCBP and will avoid conceiving from signing the ICF, while participating in the study, during dose interruptions, and for 6 months after last dose of cisplatin, or carboplatin, or etoposide or at least 105 days following CC-90011 discontinuation, whichever is the latest, even if he has undergone a successful vasectomy.
Males must agree to refrain from donating sperm while on treatment and females must agree to refrain from donating ova while on treatment and for 6 months after the last dose of cisplatin or etoposide or 105 days after last dose of CC-90011.
Subject is able to swallow pills.

Exclusion Criteria:

Subject has received anticancer therapy (either approved or investigational, including radiation with curative intent) for SCLC prior to study entry.
Subject has undergone major surgery ≤ 4 weeks prior to Cycle 1 Day 1 or has not recovered from surgery.
Subject has persistent diarrhea due to a malabsorptive syndrome (such as celiac sprue or inflammatory bowel disease) ≥ NCI CTCAE Grade 2, despite medical management), or any other significant gastrointestinal (GI) disorder that could affect the absorption of CC- 90011.
Subject with symptomatic or uncontrolled ulcers (gastric or duodenal), particularly those with a history of and/or risk of perforation and GI tract hemorrhages.
Subject with any hemorrhage/bleeding event > CTCAE Grade 2 or hemoptysis > 1 teaspoon within 4 weeks prior to the first dose.
Subject with symptomatic and untreated or unstable central nervous system (CNS) metastases.
Subject has impaired cardiac function or clinically significant cardiac diseases, including any of the following:

Left ventricular ejection fraction (LVEF) < 45% as determined by multigated acquisition (MUGA) scan or echocardiogram (ECHO).
Complete left bundle branch or bifascicular block.
Congenital long QT syndrome.
Persistent or clinically meaningful ventricular arrhythmias or atrial fibrillation.
QTcF ≥ 480 msec on Screening ECG (mean of triplicate recordings).

Subject has other clinically significant heart disease such as congestive heart failure requiring treatment or uncontrolled hypertension (blood pressure ≥ 160/95 mm Hg).
Subject is a pregnant or nursing female.
Subject has known human immunodeficiency virus (HIV) infection.
Subject has known chronic active hepatitis B or C virus (HBV, HCV) infection.
Subject with ongoing treatment with chronic, therapeutic dosing of anticoagulants (eg, warfarin, low molecular weight heparin, Factor Xa inhibitors, thrombin antagonist).
Subject has a history of concurrent second cancers requiring active, ongoing systemic treatment.
Subject has Grade 2 peripheral sensory neuropathy.
Subject with poor bone marrow reserve as assessed by Investigator.
Subject has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.
Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
Previous SARS-CoV-2 infection within 10 days for mild or asymptomatic infections or 20 days for severe/critical illness prior to C1D1.

• Acute symptoms must have resolved and based on investigator assessment in consultation with the medical monitor, there are no sequelae that would place the participant at a higher risk of receiving study treatment

Previous SARS-CoV-2 vaccine within 7 days of C1D1. For vaccines requiring more than one dose, the full series (e.g. both doses of a two-dose series) should be completed prior to C1D1 when feasible and when a delay in C1D1 would not put the study subject at risk
Subject has any condition that confounds the ability to interpret data from the study.

For the subjects treated with nivolumab:

Subject has received prior therapies targeting PD-1 or PD-L1
Subject has a history of persistent skin rash ≥ NCI CTCAE Grade 2.
Subject with an autoimmune disease, or any other condition, requiring systemic treatment with either corticosteroids within 14 days (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 30 days of enrollment. Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.

Subjects with type 1 diabetes mellitus, hypothyroidism only requiring hormone replacement, disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.

Subject has received treatment with botanical preparations (eg, herbal supplements or traditional Chinese medicines) to treat the disease under study within 2 weeks prior to randomization. Refer to Section 8.2 for prohibited therapies.
Subject has history of allergy or hypersensitivity to study drug components.
Subject has received a live/attenuated vaccine within 30 days of first treatment.

Contacts and Locations

Locations

	Site	City	Country	Postal Code
1	Hospital Le Timone	Marseille Cedex 5	France	13385
2	Local Institution - 102	Marseille Cedex 5	France	13385
3	CHU Nantes Hopital Nord Laennec	Saint-Herblain	France	44800
4	Local Institution - 103	Saint-Herblain	France	44800
5	Gustave Roussy	Villejuif CEDEX	France	94805
6	Local Institution - 100	Villejuif CEDEX	France	94805
7	Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I, G.M. Lancisi, G. Salesi	Ancona	Italy	60126
8	Local Institution - 203	Ancona	Italy	60126
9	Local Institution - 200	Bologna	Italy	40138
10	Polyclinic S. Orsola-Malpighi	Bologna	Italy	40138
11	Istituto Clinico Humanitas	Rozzano (MI)	Italy	20089
12	Local Institution - 201	Rozzano (MI)	Italy	20089
13	Local Institution - 403	Barcelona	Spain	08035
14	Vall d´Hebron University Hospital	Barcelona	Spain	08035
15	Hospital Universitario Germans Trias i Pujol	Barcelona	Spain	08916
16	Local Institution - 402	Barcelona	Spain	08916
17	Hospital Doce de Octubre	Madrid	Spain	28041
18	Local Institution - 400	Madrid	Spain	28041
19	Hospital Universitario Puerta de Hierro	Majadahonda, Madrid	Spain	28222
20	Local Institution - 406	Majadahonda, Madrid	Spain	28222
21	Hospital Universitario Virgen de la Victoria	Malaga	Spain	29010
22	Local Institution - 404	Malaga	Spain	29010
23	Hospital Clinico Universitario de Valencia	Valencia	Spain	46010
24	Local Institution - 405	Valencia	Spain	46010
25	Hospital Universitario La Fe	Valencia	Spain	46026
26	Local Institution - 401	Valencia	Spain	46026

Sponsors and Collaborators

Celgene

Investigators

Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Principal Investigator: Oscar Juan Vidal, MD, PhD, Hospital Universitario La Fe
Principal Investigator: Stefania Salvagni, MD, Azienda Ospedaliero Universitarua, Policlinico S. Orsola Malpighi
Principal Investigator: Rossana Berardi, MD, Ospedali Riuniti di Ancona
Principal Investigator: Armando Santoro, MD, IRCCS Instituto Clinic Humanitas
Principal Investigator: Benjamin Besse, MD, PhD, Gustave Roussy, Ditep